In post-Covid life, Vir looks to stomp out influenza in up to $1B BARDA contract that boosts GSK-allied mAb

With its Covid-19 monoclonal antibody sidelined in the US since April and plans for full approval no longer in the cards, Vir Biotechnology is putting more eggs into the influenza basket with a hefty-sized contract from the federal government.